The short answer
Human amylin aggregates into amyloid fibrils, which made the native peptide undeliverable. Every amylin-based medicine is therefore an engineering answer to that problem, and the two published answers take opposite approaches.
Key facts
- Core problem
- Human amylin forms amyloid fibrils
- Pramlintide's solution
- Three prolines from rat amylin
- Why rat amylin
- It does not aggregate
- Petrelintide described as
- Stable human amylin analogue
- Second problem
- Very short native half-life
- Development paper
- Fischer Munch 2025 (PMID 41217931)
Why amylin aggregates
Certain sequences are prone to stacking into ordered beta-sheet fibrils rather than remaining soluble. Human amylin is one, and islet amyloid deposits derived from it are a recognised feature of type 2 diabetes. A peptide whose natural tendency is to convert into insoluble fibrils cannot be formulated as a medicine without addressing that first.
Why proline is the classical fix
Proline's ring removes the backbone amide hydrogen and constrains rotation, which disrupts the regular hydrogen bonding a beta sheet requires. Inserting prolines is therefore a direct structural intervention against fibril formation: the residue physically cannot participate in the arrangement the aggregate needs.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The borrowed-sequence solution
Rat amylin does not aggregate, and the difference lies substantially in proline content. Pramlintide takes three positions from the rat sequence and puts them into the human one. It is an elegant solution because evolution had already produced a non-aggregating variant, and the design simply imported the relevant residues.
What a stable human analogue claims instead
Fischer Munch and colleagues describe petrelintide as a potent, stable, long-acting human amylin analogue. Retaining the human sequence while achieving stability is a harder engineering target than substituting rodent residues, and the reason to attempt it is that sequence changes can alter receptor engagement as well as aggregation behaviour.
The two problems are separate
Preventing aggregation and extending half-life are different engineering tasks with different solutions: structural disruption for the first, and typically some form of protraction such as lipidation or carrier binding for the second. A molecule solving both is solving two problems that could in principle be traded against each other.
Why this recurs across the catalogue
Aggregation is the failure mode running through several compounds on this site. IGF-1 LR3 aggregates when its fold is lost. Benzyl alcohol promotes aggregation of structured molecules. Amylin aggregates natively, without any provocation. Whether a molecule wants to stay soluble is a property of its sequence, and it determines what can be done with it.
Quick reference
| Pramlintide | Petrelintide | |
|---|---|---|
| Approach to aggregation | Prolines from rat amylin | Stable human analogue |
| Sequence origin | Human with rodent substitutions | Human |
| Duration | Short (with meals) | Long-acting |
| Status | Reached clinical use | Investigational |
Frequently asked questions
Why can't native human amylin be used as a medicine?
It aggregates into amyloid fibrils, and islet amyloid derived from it is a recognised feature of type 2 diabetes.
How does proline prevent aggregation?
Its ring removes the backbone amide hydrogen and constrains rotation, disrupting the regular hydrogen bonding a beta sheet requires.
Why attempt a human analogue rather than borrow rat residues?
Sequence changes can alter receptor engagement as well as aggregation, so retaining the human sequence avoids that trade.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedFischer Munch H et al., Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem 2025 (PMID 41217931)pubmed.ncbi.nlm.nih.gov
- PubMedBailey CJ, Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides 2026 (PMID 41747885)pubmed.ncbi.nlm.nih.gov
- PubMedMilner SJ et al., Mutations in the B-domain of IGF-I influence oxidative folding. Biochem J 1995 (PMID 8948444)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Class's Defining Safety PropertyGLP-1 amplifies insulin secretion only when glucose is already elevated. Below that threshold the signal does almost nothing - which is the whole point.
- Forcing the Channel Shut Regardless of GlucoseSulfonylureas close the beta cell's potassium channel directly, bypassing the glucose sensing step. That is precisely why they cause hypoglycaemia.
- The Number Depends on Three Things Before the DrugBackground therapy, the glucose threshold used, and how much HbA1c fell all move a hypoglycaemia figure. The compound is often the smallest factor.
- What the Class Reliably ProducesGastrointestinal effects dominate and follow from the mechanism. A 2014 review set out the profile before the current generation existed.
- Berobenatide: The Monthly GLP-1 CandidateBerobenatide is an investigational ultra-long-acting GLP-1 receptor agonist designed for monthly dosing after weekly titration. Phase 2b data and what it means.